Simultaneous Estimation of Mefenamic Acid and Ethamsylate in Tablets

G. GARG, SWARNLATA SARAF AND S. SARAF*

Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur - 492 010, India.

The simple spectrophotometric methods for the determination of mefenamic acid and ethamsylate in pharmaceutical formulations have been developed. The methods are based on the additivity of absorbances and the determination of graphical absorbance ratio at two selected wavelengths, one being the isoabsorptive point for the two drugs (301 nm) and the other being the absorption maximum of mefenamic acid (336 nm) and ethamsylate (305 nm). The Beer Lambert's law is obeyed for mefenamic acid in the concentration range 4-28 μ g/ml and for ethamsylate is 10-60 μ g/ml. Both the methods were found to be simple, rapid, and accurate and can be adopted in routine analysis of drugs in formulations. The accuracy and reproducibility of the proposed method was statistically validated by recovery studies.

Mefenamic acid, N-(2,3-Xylyl)-2-aminobenzoic acid is an analgesic and non-steroidal antiinflammatory drug with haemostatic drug ethamsylate, 2, 5-dihydrobenzene sulfonic acid used as combination drug therapy for treatment of painful menstruation. Mefenamic acid is official in BP1 USP2 and IP3, while Ethamsylate is official in BP4. The BP suggest a spectrophotometric and IP suggest a potentiometric method for the assay of mefenamic acid in bulk drugs. BP suggests potentiometric method for the estimation of ethamsylate in bulk drugs. Literature survey revealed that HPLC5 and spectrophotometric⁶ methods have been reported for the estimation of mefenamic acid and spectrophotometric⁷ and chemiluminescence⁸ methods for the ethamsylate in pharmaceutical dosage forms. The review of literature revealed that there is no simultaneous method for the estimation of the above drugs in combined dosage forms, which strongly advocates the need of simple, rapid and accurate simultaneous method for the routine analysis of the combined dosage forms.

The Shimadzu Pharmaspec 1700 UV/Vis spectrophotometer with 10 mm matched quartz cells was used for experiments. The chemicals used were of analytical grade. The commercially available marketed tablet brands Sylate-M (Emcure pharma, Pune) and E-sylate M (Saf Fermion Ltd., Kolkata) containing 500 mg of

*For correspondence E-mail: shailendrasaraf@rediffmail.com mefenamic acid and 500 mg of ethamsylate has been used for estimation.

Standard stock solution of mefenamic acid and ethamsylate were prepared separately by dissolving 100 mg each (accurately weighed) of standard mefenamic acid and ethamsylate in 10 ml 0.1 N NaOH and 90 ml of methanol. Working standard solutions (A) and (B) were further prepared by taking 1ml of stock solution of mefenamic acid and ethamsylate in 10 ml volumetric flasks and made up the volume with methanol.

Simultaneous equations method or Vierodt's method⁹ was employed as the method I. Overlain spectra of standard solutions of mefenamic acid and ethamsylate were scanned (fig. 1). Mefenamic acid shows absorption maxima at 336 nm and ethamsylate shows at 305 nm. The calibration curves for mefenamic acid and ethamsylate were prepared in the concentration range of 4-28 µg/ml and 10-60 µg/ml at both the wavelengths respectively i.e. 336 nm and 305 nm. The absorptivities/specific absorbance were determined for both the drugs at both the wavelengths and following equations were used, $A_1 =$ 231.14Cx + 29.33 Cy. (1) and A₂=331Cx + 102.50 Cy..(2), where A₁ and A₂ are absorbances at 336 nm and 305 nm, respectively, Cx and Cy are concentrations of mefenamic acid and ethamsylate, respectively, 231.14 and 331 are absorptivities of mefenamic acid at 336 nm and 305 nm, respectively, 29.33 and 102.5 are absorptivities of ethamsylate at 336 nm and 305 nm, respectively. The

TABLE 1:	COMPILAT	ION OF RESU	LIS OF STATISTIC	AL ANALISIS OF C	OWIMERC	AL FORMULA	TIONS
Method	Tablet	Tablet	Labelclaim*	Amount found*	SD*	%RSD*	SF*

Method	Tablet brand	Tablet component	Labelclaim* (mg/tab)	Amount found* (mg/tab)	SD*	%RSD*	SE*	't' Calc.*
I	А	Mefenamic acid	500	499.50	0.3184	0.0159	0.1299	0.2547
	В	Ethamsylate	500	496.47	1.6315	0.0843	0.6659	0.3052
		Mefenamic acid	500	498.25	0.2916	0.0146	0.1190	0.2332
		Ethamsylate	500	495.87	1.0447	0.0549	0.4264	0.8358
		Mefenamic acid	500	497.75	0.0966	0.0048	0.0394	0.0772
11	А	Ethamsylate	500	497.50	0.0964	0.0048	0.0393	0.0771
	В	Mefenamic acid	500	496.75	0.0665	0.0033	0.0271	0.0532
		Ethamsylate	500	496.25	0.0670	0.0034	0.0273	0.0536

*Average of six determinations, Theoretical 't' values are at 95% confidence level for (n-1) degrees of freedom. 't' (0.05,5)= 2.571, SD is standard deviation; % RSD is percent relative standard deviation, SE is standard error, Method I; Simultaneous equations and Method II; Graphical absorbance ratio method.

mixture concentration was determined by using the Eqns. (1) and (2).

In the second method (Method II), graphical absorbance ratio was used, which is based on the method used by Ghanem et al.¹⁰ and takes advantage of iso-absorptive point¹¹, of the two drugs i.e. the wavelength of equal absorptivity of the two components of the mixture. The iso-absorptive point was 301 nm (fig. 1). The other wavelength selected is the absorption maximum of one of the components. In this case it was 336 nm, the absorption maximum of mefenamic acid. The concentrations of the two components are related to the ratio of the absorbances at these two wavelengths. The absorbance of the mixture was noted at 336 nm and 301 nm. Calibration curves of mefenamic acid and ethamsylate were plotted in the concentration range 4-28 µg/ml and 10-60 µg/ml respectively (range for which Beer Lambert's law followed). The absorptivity coefficients were determined for both the drugs and the average value was taken. These values and the absorbance ratio were used to develop another set of two equations, $A_1 = 0.0392$ (Cx +



Fig. 1: Overlain spectra of mefenamic acid and ethamsylate. The (-) Line indicates mefenamic acid and (-----) indicates ethamsylate.

Cy) -(3), and $A_1 = 0.0392$ Cx { $0.3885/Q_M - 0.2003$ }-(4), where, $Q_M = A_{2/A1}$, A_1 being absorbance at 336 nm, and A_2 being absorbance at 301 nm. Cx and Cy are concentrations of mefenamic acid and ethamsylate, respectively.

Twenty tablets were weighed, and crushed to a fine powder. Powder equivalent to 100 mg of mefenamic acid and 100 mg of ethamsylate (tablet contain 500 mg mefenamic acid and 500 mg ethamsylate) was extracted quantitatively with 10 ml of 0.1N NaOH and (4x20) ml of methanol and volume was made up to 100 ml with methanol. Insoluble excipients were separated by filtration. The solution so obtained was suitably diluted with methanol so that the concentration can be read directly from the calibration curve, and the absorbances were taken at different wavelengths as stated above. Using the Eqns. 1, 2, 3 and 4 concentrations were determined.

The methods developed were found to be accurate, simple and rapid, for routine simultaneous analysis of the formulations. The first method is based on the determination of content of the mefenamic acid and ethamsylate directly from the Eqns. 1 and 2. The second method is based on the absorbance ratio and the absorptivity coefficients were determined, and the values were substituted in the Eqns. 3 and 4 to give the results. The reproducibility, repeatability and accuracy of these

TABLE 2: COMPILATION OF RESULTS OF DRUG RECOVERY STUDY

Method	Tablet brand	Percent recovery ± SD*			
		Mefenamic acid	Ethamsylate		
Ι	А	102.5 <u>+</u> 0.39	98.84 <u>+</u> 1.07		
	В	101.25 <u>+</u> 0.18	98.87 <u>+</u> 0.71		
11	А	100.10 <u>+</u> 0.11	100.05 <u>+</u> 0.13		
	В	100.25 <u>+</u> 0.08	100.35 <u>+</u> 0.08		

*Average of six determinations, SD is standard deviation, Method I; Simultaneous equations, Method II; Graphical absorbance ratio method. methods were found to be good which is evidenced by low values of standard deviation, percent relative standard deviation and standard error (Table 1). The percent range of error (at 95% confidence level) shows the precision of the methods. The accuracy and reproducibility of the proposed methods was confirmed by recovery experiments by adding known amount of the drugs to the preanalyzed formulations and reanalyzing the mixture by proposed methods (Table 2). The percent recovery obtained indicates noninterference from the excipients used in the formulations. Hence, these can be successfully applied for simultaneous estimation of mefenamic acid and ethamsylate in pharmaceutical formulations, as both the methods are simple, sensitive, precise and economical as well.

ACKNOWLEDGEMENTS

The authors wish to thank the Director, Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur for Providing necessary facilities and AICTE New Delhi for financial assistance under the scheme RPS, also thanks to Mercury Health Care Pvt. Ltd. Mumbai and Blue Cross Labs. Ltd. Mumbai for providing the authentic sample of drugs.

REFERENCES

- British Pharmacopoeia, Vol. II, Her Majesty's Stationary office London, 2003, 1198.
- The United State Pharmacopoeia XXVII22, United States Pharmacopoeial Convention INC, Twin Brook Park way, Rockville, MD, 2004, 1152.
- Indian Pharmacopoeia, Vol. I, published by the controller of publication, Govt. of India, Ministry of Health & Family Welfare, New Delhi, 1996, 459.
- British Pharmacopoeia, Vol. I, Her Majesty's Stationary office London, 2003, 729.
- Rowni, M.R., Asadipour, A., Ardakani, Y.H. and Aghdas, F., J. Chromatogr. B., 2004, 800, 189.
- 6. Dinc, E., Yucesoy, C. and Onur, F., J. Pharm. Biomed. Anal., 2002, 28, 1091.
- 7. El-Shabrawy, Y., El-Enany, N. and Salem, K., Farmaco, 2004, 59, 803.
- Yang, F., Zhang, C., Baeyens, R.G. and Zhang, X., J. Pharm. Biomed. Anal., 2002, 30, 473.
- Beckett, A.H. and Stenlake, J.B., In; Practical Pharmaceutical Chemistry, 4th Edn., Vol. II, CBS Publishers and Distributors, New Delhi, 1997, 278, 307.
- 10. Ghanem, A., Meshali, M. and Foda, A., J. Pharm. Pharmacol., 1979, 31, 122.
- 11. Pernarowski, M., Knevel, A.M. and Christian, J.E., J. Pharm. Sci., 1960, 50, 943.

Accepted 6 April 2007 Revised 3 July 2006 Received 23 November 2005 Indian J. Pharm. Sci., 2007, 69 (2): 279-281